Cancer Res January 15 2017 77 (2) 219-220;
In vivo fluorescent imaging calculates chemotherapeutic permeability into tumors in the brain and details a new hypothesis on how monoclonal antibodies work in brain metastases of breast cancer.
This imaging study elucidates stromal adaptations in premetastatic lung sites, enabling an objective recognition of tumor metastatic potential.
This study illustrates the potential of a robust conjugation platform for the preparation of antibody-drug conjugates that have potent anticancer properties.
These findings reveal a targetable mechanism that could be exploited to block metastasis of colorectal cancer to bone, an essentially untreatable form of the disease.
These findings identify independent cooperating pathways through which macrophages control the speed and persistence of cancer cell migration in 3D tissue microenvironments.
These findings elucidate a novel contribution of basophils to tumor rejection that can be exploited to enhance the efficacy of cancer immunotherapy.
In identifying the bidirectional MIF/IL8 survival mechanism between AML cells and bone marrow-derived mesenchymal stromal cells, this study provides a rationale to therapeutically target this protumoral feedback loop.
Immune stimulating polyI:C and CpG oligodeoxynucleotides that have been used safely in clinical trials are found to powerfully enhance the therapeutic efficacy of HER2 monoclonal antibody drugs.
These findings offer preclinical proof of concept for combined inhibition of two key growth and survival signaling pathways as a therapeutic strategy to kill pancreatic cancer cells.
A key mediator of metastasis in clear cell renal cell carcinoma acts via a noval regulatory axis, suggesting a general strategy to improve management of this disease.
In elucidating how the tumor suppressor p14ARF is degraded, this study has implications for prognosis and treatment or p14ARF-expressing lung cancers.
Opposing effects of calcium and vitamin D in prostate cancer progression provide a paradigm to evaluate calcium intake and to consider vitamin D supplementation in patients on active surveillance for low-risk prostate cancer.
An siRNA-based screen of neural crest cells from which melanocytes are derived identifies candidate targets to attack melanoma and to overcome drug resistance in this disease.
Metabolic insights into how the androgen receptor affects the estrogen-related receptor ERRg in prostate cancer suggests new routes for its therapeutic management.
By providing a detailed mutational portrait of pediatric acute lymphocytic leukemias, this study suggests how to target drug-resistant tumors and develop less toxic targeted therapies.
This study suggesting new insights into tumor suppressor interplay in epigenetic regulation of neuroendocrine tumors may impact decisions about their therapy.
These provocative results identify an intracellular function of a matricellular protein in directing cytosolic regulation of androgen receptor signaling and prostate cancer progression.
Genetic associations identified in this study may enable a more focused study of genotypic differences that can explain the disparity in BRCA incidence and mortality rates between Asian and Caucasian patient populations in the U.S.
These findings reveal a novel role for Plk4 in promoting cancer invasion and metastasis through regulation of Arp2/3-mediated actin cytoskeletal rearrangement, thus validating Plk4 as a viable therapeutic target in cancer treatment.
This potentially seminal study suggests an answer to the long-standing question of why germline BRCA1 mutations cause tissue-specific tumors, with immediate implications for evaluating suitable antioxidant modalities as a strategy to mitigate the risks of familial breast cancer increased by BRCA1 mutation.
This study uses a computational approach to discover synergistic combinations between targeted drugs to treat breast cancer, with the capability of providing broadspectrum utility across several cancer types.
In providing a comprehensive analysis of the specificity of epigenetic therapy in cancer, this study shows how combined targeting of DNA and histone methylation may offer an improved efficacy of this type of therapy for cancer treatment.
This study shows how yet another cancer celltargeting strategy actually mediates its efficacy by modulating the immune system, a growing theme in targeted drug development.
These findings show how a survival signaling pathway mediated by a key mitotic regulator can be targeted to enhance the chemosensitivity of deadly leukemias.
Analysis of an aggregate genomic dataset for pediatric tumors may illuminate novel therapeutic targets, validate oncogenic mechanisms, guide treatment decisions, and design appropriate clinical trials for children with cancer.
These findings show how novel low-dose administration of mTOR inhibitors can effectively cooperate with, rather than antagonize immunotherapy, resuscitating interest in mTOR-targeting therapies, which have otherwise been mainly disappointing in clinical trials.
By identifying a novel tumor suppressor gene that sensitizes cancer cells to paclitaxel, this study may have implications for timed chronotherapy of head and neck cancer, where this drug is used.
These findings unravel a novel mechanism of resistance to antiestrogen drugs in ER+ breast cancer cells, with potential prognostic and therapeutic implications.
This study describes a noninvasive imaging technique to rapidly assess skin toxicity caused by diverse cancer treatments, addressing a common type of side effect experienced by patients receiving cancer therapy.
Through a guided screen of FDA-approved and investigational drugs, this study suggests new treatments for aggressive triple-negative breast cancers that can be immediately translated to clinical trials.
These findings identify a novel EGFR ligand and candidate prognostic marker for metastasis in nasopharengeal carcinoma.